Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer.

CONCLUSION: Use of bevacizumab caused moderate adverse effects, none of which was life-threatening. PMID: 29135093 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research